Today’s AI Top Pick: PODD

7/16/2026 · Turnaround screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · PODD80%181 resolved forecasts · 45d window · verify →

Today's pick · TurnaroundPODDBUY NOW8.9 / 107/16/2026

Insulet (PODD) is the cleanest turnaround setup in the pool because every ingredient lines up TODAY: a deeply oversold weekly (-35.12% drawdown from the 21-bar high, weekly pos_in_range only 14.81%) is being met with a forecast tape that is uniformly bullish across the 4h/1d/1wk horizons — 1d forecasts of +10.45%/+50.65%/+62.44% and 1wk of +10.32%/+33.80%/+52.31% are among the strongest mid/long numbers on the entire board, and unlike HSAI or ORCL the weekly forecast is NOT negative. Bullish_prob is 1.0, near_term_bullish is 1.0, and fundamental_score is a maxed-out 8. Fundamentals corroborate the tape: fwdPe 19.78, PEG 0.74, ROE 23%, profitMargin 10.44%, salesYoY +31.93%, epsNextY +24.34%, and analyst recom of 1.44 with 47.5% target upside. This is a real, GAAP-profitable medtech leader (Omnipod) trading at growth-at-a-reasonable-price after a -45% one-year drawdown — exactly what the turnaround screen was built to surface, not a speculative shell. The news backdrop is a tailwind, not a landmine. July 16 ChartMill flagged PODD as 'A Quality Affordable Growth Stock With Strong Earnings Momentum,' the Calm partnership (July 14) is a soft brand catalyst, and the broader CGM/BGM market is being pegged at $39.4B by 2035 (8.9% CAGR). Contrast this with FUTU (a mirror-image forecast setup — but sunk by a DOJ probe and class actions on July 3), or SE (COO sold $4.5M and near-term forecasts are -18% to -21%), or ORCL (weekly forecasts still negative). PODD has no such overhang. Why today, not later: the daily is at pos_in_range 82.4% with only -2.72% drawdown from the recent high, meaning momentum has already turned on the shorter frames while the weekly still shows massive room to run (-35% off the high, pos 14.8%). That is the textbook multi-timeframe compression that resolves upward — chasing after the weekly re-rates means giving up the biggest chunk of the +52% long forecast. Buy the bounce while the weekly is still cheap.

Entry zone

$156–$162 (current $160; add on any dip toward the 4h dd zone near $153)

Stop loss

$146 (below the recent 4h swing and roughly -8.75% — invalidates the daily reversal)

First target

$178–$182 (+11–14%, aligns with 1d fc_short +10.45% and reclaim of prior consolidation)

Longer target

$215–$240 (1wk fc_mid +33.8% to fc_long +52.3%; also matches analyst target upside of 47.5%)

Risks

Near-term 1h forecasts are actually negative (-8.88%/-5.17%/-2.74%) — expect chop or a shakeout to $155 before the move
Deep -45.07% one-year drawdown suggests a real fundamental scare; any Q2 guidance miss could restart the downtrend
shortFloat 7.04% is moderate but not trivial in a medtech name if a competitive/reimbursement headline hits
debtEq 0.73 is fine but not fortress; rising-rate reprice would compress the fwdPe 19.78 multiple
Insulin-pump competitive landscape (Tandem, Medtronic, potential Abbott/Dexcom pump entrants) can undermine 31.9% salesYoY trajectory

Honorable mentions

HSAIBest pure momentum forecast profile — 1d fc +27.8/49.8/42.9 and pos_in_21bar_range only 9-32% on 4h/1wk (no chase). 8-for-1 split approval July 15 is a retail catalyst. Only reason it's not #1: weekly forecast turns negative (fc_mid -5.25%, fc_long -3.37%), meaning the pop may not extend to a multi-week swing, and PE 283 is optically ugly.

ORCLRSI 30.42 is genuinely oversold, ROE 54.28%, fwdPe 12.15, targetUpsidePct 92.3%, and 1d forecasts +32.44%/+48.81% with pos_in_range at 9%. Held back by still-negative weekly forecasts (-4.98/-3.92/-0.52) and 4h/1wk drawdowns of -40%. Great value, but tape hasn't fully turned like PODD's has.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PODD	BUY NOW	8.9	Multi-TF alignment with 1d fc +50.65% and 1wk fc +33.8%, deep -35% weekly drawdown, fundamental_score 8, positive news — cleanest setup.
2	HSAI	BUY NOW	8.4	Massive 4h/1d forecasts (+44.9%/+49.8%) with pos_in_range 9-32% and an 8-for-1 split catalyst; only knock is a soft weekly forecast.
3	ORCL	BUY NOW	8.0	Oversold RSI 30, fwdPe 12.15, 92% analyst upside, 1d fc +48.8% long — a value+forecast combo on a $381B name.
4	TMDX	BUY NOW	7.6	Weekly dd -47.8% into 1d fc +51.7%/+58.4%; ROE 45%, profitMargin 27%, but 23.57% short float means volatility.
5	CELH	BUY PULLBACK	7.3	Deep -43.56% weekly drawdown, 1d fc +30.79%/+48.09%/+54.41%, positive 'undervalued' coverage — wait for 4h to base.
6	BILI	BUY PULLBACK	7.2	Buyback catalyst and 1d fc +39.1% mid, but daily pos_in_range 100% — don't chase, wait for pullback to $17.
7	WING	BUY PULLBACK	7.0	1d fc +56.7%/+66.4% off -43.6% weekly drawdown; pos_in_range 0 = capitulation. Buy dip after earnings clarity.
8	CALX	BUY PULLBACK	6.9	1d fc +29.6%/+33.9% and earnings next week — catalyst risk, size accordingly.
9	SRAD	BUY PULLBACK	6.7	PEG 0.48, epsNextY +69.7%, 1d fc_mid +35.7%; JPM PT raise, but weekly forecast flat.
10	CHWY	BUY PULLBACK	6.6	1d fc +37.98%/+49.06% and 1wk fc +30% with roe 63.8%; near daily high, wait for retest of $19.50.
11	STEP	BUY PULLBACK	6.4	salesYoY +69.9%, 1d fc +23.3% mid; ROE is a red herring due to structure, but negative operMargin -45% requires patience.
12	MNDY	BUY PULLBACK	6.2	Weekly dd only -4% but 1d fc +54.5% mid; BTIG PT cut to $105 shows sentiment resetting lower.
13	INTR	BUY PULLBACK	6.1	PEG 0.23, fwdPe 5.68, targetUpsidePct 69.4%, 1d fc +38% — cheap but 1h is soft, wait for 4h confirmation.
14	MLCO	BUY PULLBACK	5.9	PEG 0.33, 1wk fc +19.9%/+42.2%/+50.9% off -12.3% dd; small-cap ($2B) illiquid, need patience.
15	KVYO	WAIT	5.7	1wk fc +22.6/+20.8/+30.7 but pos_in_range 100% on 1h/4h/1d — chasing the top.
16	ONON	WAIT	5.5	1d fc only +11%/+11%, near_term_bullish 0; JPM Overweight resumption is late.
17	NOW	WAIT	5.4	Big cap, 1wk fc_long +22.7% but 1h/4h forecasts negative — no urgency to chase $106.
18	MELI	WAIT	5.3	Only -8.5% YTD, expected_return 17%; fully valued relative to peers here.
19	UBER	WAIT	5.2	PEG 3.44, 1wk fc mid/long negative; Delivery Hero deal adds integration risk.
20	HLI	WAIT	5.1	pos_in_range 100% on 1h with modest forecasts — at the top, no juice.
21	KKR	WAIT	5.0	Pos_in_range 100% on 4h/1d and 1wk fc turns negative -2.86/-5.24/-6.20 — the bounce is already in.
22	ARES	WAIT	4.9	1wk fc -1.2/-7.0/-10.2; strong 4h base but forward tape says no.
23	DKNG	WAIT	4.8	1d fc +48% long but PE 419, fundamental_score only 3.75 and profitMargin 0.93%.
24	TOST	AVOID	4.5	1h/4h/1wk forecasts all deeply negative (-11 to -21%); RSI 69.5 near overbought, pos 100% — screams sell-the-rip.
25	FICO	WAIT	4.5	1wk forecasts -7/-9/-14; earnings upcoming = binary event.
26	SPOT	AVOID	4.3	1wk fc -12.5/-23.9/-27.9 with pos_in_range 92% on daily — top-of-the-tape distribution.
27	GRAB	WAIT	4.2	CEO sold 400k shares, 1h/4h forecasts negative — insider timing is a yellow flag.
28	MIR	WAIT	4.1	PE 173, roe 1.5%, profitMargin 2.56%; two brokers cut PTs to $25 — weak thesis.
29	SE	AVOID	3.8	1h fc -18.7/-21.4/-21.8 and 4h -8.5/-19.3/-12.5; COO dumped $4.5M — forecast tape screaming sell.
30	FUTU	AVOID	3.2	1d fc +50%/+57% is elite, but DOJ probe + class actions announced July 3 is a disqualifying landmine — pass until the legal picture clears.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord